Loading provider…
Loading provider…
Pediatric Pulmonology Physician in Lexington, KY
NPI: 1245259035Primary Practice Location
UNIVERSITY OF KENTUCKY HOSPITAL
800 Rose St, Lexington, KY
Primary Employer
Kentucky Medical Services Foundation, Inc
kmsf.com
HQ Phone
Get MD Michael's Phone Numberphone_androidMobile
Get MD Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardKY State Medical License
KY State Medical License
1990 - 2026
WV State Medical License
2012 - 2026

American Board of Internal Medicine
Critical Care Medicine

American Board of Internal Medicine
Pulmonary Disease

American Board of Internal Medicine
Sleep Medicine
University Of Kentucky College Of Medicine
medicine.uky.edu
Medical School
Until 1989
Residency • Internal Medicine
1990 - 1994
Fellowship • Pulmonary Disease and Critical Care Medicine
1994 - 1997
Wayne State University School Of Medicine
med.wayne.edu
Internship • Internal Medicine
1989 - 1990
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 51 | 92 |
| 2 | 94010Measurement and graphic recording of total and timed exhaled air capacity | 41 | 76 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 30 | 156 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 22 | 39 |
| 5 | 99214Established patient office or other outpatient visit, 30-39 minutes | 14 | 18 |
Authors: Dennis Stokes, Bruce Marshall, Jane L Burns, Lisa Saiman
Journal: Pediatr Pulmonol
Publication Date: 2012-01-03
Tolerance and intolerance to continuous positive airway pressure.
Authors: Anstead, M, Phillips, B, Buch, K
Journal: Curr Opin Pulm Med
Characterization of macrophage activation states in patients with cystic fibrosis
Lead Sponsor: ProQR Therapeutics
Collaborators: European Commission
Intervention / Treatment: DRUG: Placebo, DRUG: QR-010
Lead Sponsor: Steven M Rowe
Lead Sponsor: CF Therapeutics Development Network Coordinating Center
Collaborators: Cystic Fibrosis Foundation
Intervention / Treatment: DRUG: azithromycin 250 mg tablets, DRUG: placebo tablets